期刊
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 63, 期 -, 页码 96-102出版社
ELSEVIER
DOI: 10.1016/j.ejps.2014.06.011
关键词
Nanoparticles; Intravenous; Drug delivery; Arterial pressure
资金
- Academy of Finland [117906]
- University of Eastern Finland
- Northern-Savo Cultural foundation (MV)
- Academy of Finland (AKA) [117906, 117906] Funding Source: Academy of Finland (AKA)
Intravenously administered nanocarriers are widely studied to improve the delivery of various therapeutic agents. However, recent in vivo studies have demonstrated that intravenously administered nanocarriers that do not contain any drug may affect cardiovascular function. Here we provide an example where the drug and the nanocarrier both affect the same cardiovascular parameters following intravenous administration. The peptide ghrelin antagonist (GhA) increases arterial pressure, while thermally hydrocarbonized porous silicon nanoparticles (THCPSi) transiently decrease it, as assessed with radiotelemetry in conscious rats. As a result, intravenous administration of GM-loaded THCPSi nanoparticles partially antagonized GM activity: arterial pressure was not increased. When the cardiovascular effects of GM were blocked with atenolol pretreatment, GM-loaded nanoparticles reduced arterial pressure to similar extent as drug-free nanoparticles. These data indicate that the biological activity of a drug delivered within a nanocarrier may be obscured by the biological responses induced by the nanocarrier itself. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据